Our mission

The European Atherosclerosis Society (EAS) was founded in 1964, to “advance and exchange knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”.

The Society’s main activities are focused on four main areas:

  • The dissemination of up-to-date knowledge of the pathophysiology underlying atherogenic dyslipidemia and premature atherosclerosis
  • The prevention, diagnosis and treatment of atherosclerotic vascular disease in non-diabetic and diabetic subjects
  • The promotion of cutting-edge basic and clinical research in the field of atherosclerosis and related metabolic diseases such as Metabolic Syndrome and Type 2 Diabetes
  • The support, promotion, and organization of scientific Congresses and Workshops both within and outside Europe on topics related to atherosclerosis in its widest sense. These include:
    - Lipid, lipoprotein and cholesterol metabolism
    - Vascular biology
    - Mechanisms underlying atherosclerosis and clinical cardiovascular events, particularly myocardial infarction
    - Cerebro- and peripheral vascular disease
    - Genetics of atherosclerotic vascular diseases
    - Plaque imaging modalities
    - Pharmacotherapy of lipid disorders
    - Prevention of atherosclerotic vascular disease

Future goals

With the dramatic worldwide progression of the pandemic of metabolic diseases including obesity and diabetes, and premature atherosclerosis and cardiovascular disease on the one hand, and with the aging of the European population on the other, atherosclerosis has become a major health concern.

In this light, EAS has joined forces with other societies and groups actively involved in this field. Our common goals are to prevent the disease and to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. The EAS is Europe’s resource for expertise in these areas, as well as in inherited disorders of lipid metabolism associated with high cardiovascular risk. With our partners, we will promote European prevention projects and approach both public and private sectors for support.